Answers are grounded in this paper and cite their sources.
5-aminolevulinic acid (5-ALA) is a prodrug that results in the fluorescence of high-grade gliomas relative to the surrounding brain parenchyma. 5-ALA has been increasingly utilized in fluorescence-guided surgery for these tumors, and its intraoperative use has been associated with a significantly improved extent of resection and progression-free survival. This review outlines the growing body of evidence that has culminated in the recent Food and Drug Administration approval of 5-ALA, as well as emerging applications for this agent.
No takes yet. Share an insight, caveat, or question.
Lakomkin et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: